October 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in October 2022 for investigational products in development.
The table provided is a review of notable updates that occurred in October 2022 for investigational products in development.
Intranasal epinephrine was found to be absorbed quicker.
Cost-sharing still substantial for some using nonbranded auto-injectors, such as those enrolled in high-deductible health plans
By clarifying the risk for anaphylaxis, study findings can contribute to the choice of IV iron preparations, according to investigators.
Allergy treatment gets over-the-counter approval; Anaphylaxis treatment recalled; Phase 3 trial results for investigational sciatica treatment; FDA alert regarding at-home COVID-19 tests; And the resubmitted Biologics License Application for teplizumab for type 1 diabetes is accepted.
Certain lots of Symjepi (epinephrine) Injection 0.15mg and 0.3mg prefilled single-dose syringes are being recalled.
The designation is supported by data from Part 1 of the EPIPHAST study, which compared the pharmacokinetics and pharmacodynamics of AQST-109 to intramuscular epinephrine in healthy adults.
Janssen adenovirus type 26 vectored vaccine may be considered for individuals who self-report PEG allergy
Guidance relates to risks for allergic reactions for mRNA (Moderna and Pfizer) and adenovirus vector (Johnson & Johnson) COVID-19 vaccines
Most recipients with anaphylaxis had allergy histories, with 31 percent having prior anaphylaxis